Overview
Unverified · drafted by AI from the sources cited below
Definition
Amyloidosis is a group of sporadic, familial and/or inherited, degenerative, and infectious disease processes linked by the common theme of abnormal protein folding and deposition of amyloid.1 As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function.1 Symptomatic cardiac amyloidosis can occur with or without peripheral neuropathy.2
Diagnosis and risk stratification
Documents from 5 scientific societies include an algorithm to establish a diagnosis of cardiac amyloidosis.1 These guidelines emphasize noninvasive diagnosis through the combined use of bone scintigraphy and the exclusion of a monoclonal protein.1 Nevertheless, documents from these societies diverge on specific details regarding diagnosis and risk stratification.1
New research on Cardiac amyloidosis
Chronic Exercise Accelerates Disease Progression in a Rat Model of Desminopathy
Journal of Cachexia Sarcopenia and Muscle — Langer H — Nov 2026
Landmark trials
Primary results of 2 trials behind the evidence on cardiac amyloidosis, as each trial’s own publication reports them.
Left of the line at 1 favours the intervention; square size tracks trial size.Favours the interventionNo significant differenceFavours the comparator
0.250.512
HELIOS-Boverall population
vutrisiran vs placebo · 655 patients · N Engl J Med 2025
In patients with ATTR-CM
Primary outcome: a composite of death from any cause and recurrent cardiovascular events
Key papers
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia
Journal of the American College of Cardiology — Arenal Á
188 citations · 2022 · among the most cited on Cardiac amyloidosis
First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial
Circulation
173 citations · 2022 · among the most cited on Cardiac amyloidosis
How this page is built
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
